Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Autografting

Autologous stem cell transplantation in patients with chronic lymphocytic leukaemia: the Finnish experience

Bone Marrow Transplantation volume 37, pages 1093–1098 (2006)Cite this article

Abstract

Although autologous stem cell transplantation (ASCT) has gained some popularity as a treatment option in patients with chronic lymphocytic leukaemia (CLL), limited multicentre data are available on the feasibility and efficacy of this approach. Between January 1995 and June 2005, 72 patients with CLL received ASCT in five Finnish centres. There were 45 men and 27 women with a median age of 57 years (38–69). The median time from diagnosis to ASCT was 32 months (6–181) and the median number of prior regimens 1 (1–4). All patients received blood stem cell grafts and CD34+ selection had been performed in 44 patients (61%). The most common high-dose regimen was a total body irradiation plus cyclophosphamide (38 patients, 53%). No early treatment-related deaths were observed. With a median follow-up of 28 months from ASCT, a relapse or progression has been observed in 27 patients (37%). The projected progression-free survival is 48 months (confidence interval (CI) 30–66). The projected median overall survival is 95 months (CI 74–101) from ASCT and is not influenced by graft selection or conditioning regimen used. Autologous stem cell transplantation is a feasible treatment option for CLL. Randomized trials against alternative treatments are needed to assess the impact of ASCT on the clinical course of CLL.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. Döhner H, Stilgenbauer S, Benner A, Leupolt E, Krober A, Bullinger L et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000; 343: 1910–1916.

    Article  PubMed  Google Scholar 

  2. Hamblin TJ, Davis Z, Gardiner A, Oschier DG, Stevenson FK . Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999; 94: 1848–1854.

    CAS  PubMed  Google Scholar 

  3. Rai KR, Peterson BL, Appelbaum FR, Kolitz J, Elias L, Shepherd L et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 2000; 343: 1750–1757.

    Article  CAS  PubMed  Google Scholar 

  4. Eichhorst BF, Busch R, Hopfinger G, Pasold R, Hensel M, Steinbrecher C et al. Fludarabine plus cyclophosphamide versus fludarabine alone in first line therapy in younger patients with chronic lymphocytic leukemia. Blood 2006; 107: 885–891.

    Article  CAS  PubMed  Google Scholar 

  5. Lundin J, Kimby E, Björkholm M, Broliden PA, Celsing F, Hjalmar V et al. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood 2002; 100: 768–773.

    Article  CAS  PubMed  Google Scholar 

  6. Keating MJ, Flinn I, Jain V, Binet JL, Hillmen P, Byrd J et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 2002; 99: 3554–3561.

    Article  CAS  PubMed  Google Scholar 

  7. Elter T, Borchmann P, Schulz H, Reiser M, Trelle S, Schnell R et al. Fludarabine combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial. J Clin Oncol 2005; 23: 7024–7031.

    Article  CAS  PubMed  Google Scholar 

  8. Keating MJ, O’Brien S, Albitar M, Lerner S, Plunkett W, Giles F et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 2005; 23: 4009–4012.

    Article  Google Scholar 

  9. Wierda W, O’Brien S, Wen S, Faderl S, Garcia-Manero G, Thomas D et al. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol 2005; 23: 4070–4078.

    Article  CAS  PubMed  Google Scholar 

  10. Dreger P, von Neuhoff N, Kuse R, Sonnen R, Glass B, Uharek L et al. Early stem cell transplantation for chronic lymphocytic leukaemia: a chance of cure? Br J Cancer 1998; 77: 2201–2207.

    Article  Google Scholar 

  11. Dreger P, Montserrat E . Autologous and allogeneic stem cell transplantation for chronic lymphocytic leukemia. Leukemia 2002; 16: 985–992.

    Article  CAS  PubMed  Google Scholar 

  12. Jabbour E, Keating MJ, Champlin RE, Khouri IF . Stem cell transplantation for chronic lymphocytic leukaemia: should not more patients get a transplant. Bone Marrow Transplant 2004; 34: 289–297.

    Article  CAS  PubMed  Google Scholar 

  13. Paneesha S, Milligan DW . Stem cell transplantation for chronic lymphocytic leukaemia. Br J Haematol 2005; 128: 145–152.

    Article  CAS  PubMed  Google Scholar 

  14. Rabinowe SN, Soiffer RJ, Gribben J, Daley H, Freedman AS, Daley J et al. Autologous and allogeneic bone marrow transplantation for poor prognosis patients with B-cell chronic lymphocytic leukemia. Blood 1993; 82: 1366–1376.

    CAS  PubMed  Google Scholar 

  15. Khouri IF, Keating MJ, Vriesendorp HM, Reading CL, Przepiorka D, Huh YO et al. Autologous and allogeneic bone marrow transplantation for chronic lymphocytic leukemia: preliminary results. J Clin Oncol 1994; 12: 748–758.

    Article  CAS  PubMed  Google Scholar 

  16. Ritgen M, Lange A, Stilgenbauer S, Dohner H, Bretscher C, Bosse H et al. Unmutated immunoglobulin variable heavy-chain gene status remains an adverse prognostic factor after autologous stem cell transplantation for chronic lymphocytic leukemia. Blood 2003; 101: 2049–2053.

    Article  CAS  PubMed  Google Scholar 

  17. Gribben JG, Zahrieh D, Stephans K, Bartlett-Pandite L, Alyea EP, Fisher DC et al. Autologous and allogeneic stem cell transplantation for poor risk chronic lymphocytic leukemia. Blood 2005; 106: 4389–4396.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Milligan DW, Fernandes S, Dasgupta R, Davies FE, Matutes E, Fegan CD et al. Results of MRC pilot study show autografting for younger patients with chronic lymphocytic leukaemia is safe and achieves a high percentage of molecular responses. Blood 2005; 105: 397–404.

    Article  CAS  PubMed  Google Scholar 

  19. Cheson BD, Bennett JM, Grever M, Kay N, Keating MJ, O’Brien S et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996; 87: 4990–4997.

    CAS  PubMed  Google Scholar 

  20. Itälä M, Pelliniemi TT, Rajamäki A, Remes K . Autologous stem cell transplantation in B-CLL: response to chemotherapy prior to mobilization predicts the stem cell yield. Bone Marrow Transplant 1997; 19: 647–651.

    Article  PubMed  Google Scholar 

  21. Michallet M, Thiebaut A, Dreger P, Remes K, Milpied N, Santini G et al. Peripheral blood stem cell (PBSC) mobilization and transplantation after fludarabine therapy in chronic lymphocytic leukaemia (CLL): a report of the European Blood and Marrow Transplantation (EBMT) CLL subcommittee on behalf of the EBMT Chronic Leukaemia Working Party (CLWP). Br J Haematol 2000; 108: 595–601.

    Article  CAS  PubMed  Google Scholar 

  22. Tournhilhac O, Cazin B, Lepretre S, Divine M, Maloum K, Delmer A et al. Impact of frontline fludarabine and cyclophosphamide combined treatment on peripheral blood stem mobilization in B-cell chronic lymphocytic leukaemia. Blood 2004; 103: 363–365.

    Article  Google Scholar 

  23. Altes A, Sierra J, Esteve J, Martin-Henan G, Marin P, Sureda A et al. CD34+-enriched-CD19+-depleted autologous peripheral blood stem cell transplantation for chronic lymphoproliferative disorders: high purging efficiency but increased risk of severe infections. Exp Hematol 2002; 30: 824–830.

    Article  CAS  PubMed  Google Scholar 

  24. Dreger P, Stilgenbauer S, Benner A, Ritgen M, Krober A, Kneba M et al. The prognostic impact of autologous stem cell transplantation in patients with chronic lymphocytic leukaemia: a risk-matched analysis on the VH gene mutational status. Blood 2004; 103: 2850–2858.

    Article  CAS  PubMed  Google Scholar 

  25. Rassenti LZ, Huynh L, Toy TL, Chen L, Keating MJ, Gribben JG et al. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med 2004; 351: 893–901.

    Article  CAS  PubMed  Google Scholar 

  26. Byrd JC, Gribben JG, Peterson BL, Grever MR, Lozanski G, Lucas DM et al. Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adopted therapy. J Clin Oncol 2006; 24: 437–443.

    Article  CAS  PubMed  Google Scholar 

  27. Calin GA, Ferracin M, Cimmino A, di Leva G, Shimizu M, Wojcik SE et al. A microRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med 2005; 353: 1768–1771.

    Article  Google Scholar 

  28. Del Poeta G, Del Principe MI, Irno Consalvo MA, Maurillo L, Buccisano F, Venditti A et al. The addition of rituximab to fludarabine improves clinical outcome in untreated patients with ZAP-70-negative chronic lymphocytic leukemia. Cancer 2005; 104: 2743–2752.

    Article  CAS  PubMed  Google Scholar 

  29. Dreger P, Brand R, Hansz J, Milligan D, Corradini P, Finke J et al. Treatment-related mortality and graft-versus-leukemia activity of allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning. Leukemia 2003; 17: 841–848.

    Article  CAS  PubMed  Google Scholar 

  30. Schetelig J, Thiede C, Bornhauser M, Schwerdtfeger R, Kiehl M, Beyer J et al. Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem cell transplantation: the Cooperative German Transplant Study Group. J Clin Oncol 2003; 21: 2747–2753.

    Article  CAS  PubMed  Google Scholar 

  31. Ritgen M, Stilgenbauer S, von Neuhoff N, Humpe A, Gruggemann M, Pott C et al. Graft-versus-leukemia activity may overcome therapeutic resistance of chronic lymphocytic leukaemia with unmutated immunoglobulin variable heavy-chain gene status: implication of minimal residual disease measurement with quantitative PCR. Blood 2004; 104: 2600–2602.

    Article  CAS  PubMed  Google Scholar 

  32. Moreno C, Villamor N, Colomer D, Esteve J, Martino R, Nomdedeu J et al. Allogeneic stem-cell transplantation may overcome the adverse prognosis of unmutated VH gene in patients with chronic lymphocytic leukaemia. J Clin Oncol 2005; 23: 3433–3438.

    Article  PubMed  Google Scholar 

  33. Sorror ML, Maris MB, Sandmaier BM, Storer BE, Stuart MJ, Hagenbart U et al. Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukaemia. J Clin Oncol 2005; 23: 3819–3829.

    Article  PubMed  Google Scholar 

  34. Kuittinen T, Wiklund T, Remes K, Elonen E, Lehtinen T, Kuittinen O et al. Outcome of progressive disease after autologous stem cell transplantation in patients with non-Hodgkin's lymphoma: a nation-wide survey. Eur J Haematol 2005; 75: 199–205.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The study was supported by a grant from the Blood Disease Research Foundation in Finland.

Author information

Authors and Affiliations

  1. Department of Medicine, Kuopio University Hospital, Kuopio, Finland

    E Jantunen & T Nousiainen

  2. Department of Medicine, Turku University Central Hospital, Turku, Finland

    M Itälä & K Remes

  3. Department of Medicine, Oulu University Hospital, Oulu, Finland

    T Siitonen & P Koistinen

  4. Department of Medicine, Helsinki University Central Hospital, Helsinki, Finland

    E Juvonen & L Volin

  5. Department of Medicine, Tampere University Hospital, Tampere, Finland

    E Koivunen

Authors
  1. E Jantunen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M Itälä
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. T Siitonen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. E Juvonen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. E Koivunen
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. P Koistinen
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. L Volin
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. K Remes
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. T Nousiainen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to E Jantunen.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jantunen, E., Itälä, M., Siitonen, T. et al. Autologous stem cell transplantation in patients with chronic lymphocytic leukaemia: the Finnish experience. Bone Marrow Transplant 37, 1093–1098 (2006). https://doi.org/10.1038/sj.bmt.1705375

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1705375

Keywords

This article is cited by

Search

Advanced search

Quick links